IUC26700-80

Abstract Code: IUC26700-80   Outcomes of dual immunotherapy versus other first line treatments for metastatic renal carcinoma Woods 1, S. Growcott 1, A. Gee 1 (1) Royal United Hospital, Bath – United Kingdom   Background: The Checkmate trial...

IUC26699-97

Abstract Code: IUC26699-97   Who Gets Left Out? The Real-World Eligibility Gap in Landmark Metastatic Renal Cell Carcinoma Trials Zeb 1 (1) university Hospital Birmingham – United Kingdom   Who Gets Left Out? The Real-World Eligibility Gap in Landmark...

IUC26697-95

Abstract Code: IUC26697-95 First Line Tyrosine Kinase Inhibitors (TKIs) in metastatic Renal Cell Cancer (mRCC)- A regional cancer Centre experience. Gul 1, O. Oghenevwede 2, E. Fetherston 1, O. Shahin 1, K. Kumar 2 (1) Freeman Hospital, Newcastle upon Tyne –...

IUC26695-93

Abstract Code: IUC26695-93   Real-world Outcomes of First-line Immune Checkpoint Inhibitor–Tyrosine Kinase Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: A Regional Cancer Centre Experience Gul 1, E. Fetherston 1, O. Oghenevwede 2, O. Shahin 3,...

IUC26694-92

Abstract Code: IUC26694-92   Stereotactic Body Radiotherapy and Immunotherapy for Metastatic Renal Cell Carcinoma Croatian Uro-Oncology Network Experience Brcic 1, J. Murgic 1, K. Brcic 2, M. Lekic 3, I. Tomaskovic 4, M. Jazvic 1, D. Schwarz 3, M. Penc 5, T....

IUC26693-91

Abstract Code: IUC26693-91   CHOLESTEROL HOMEOSTASIS AND IMMUNE-INFLAMMATORY PROFILES IN PATIENTS WITH mRCC RECEIVING IMMUNOTHERAPY Tuttobene 1, M. Maffezzoli 2, G. Leali 1, M. Pluchino 3, E. Favari 4, G. Mazzaschi 3, F. Pecci 3, M. Tiseo 3, M. Di Maio 5, S. Buti...
error: Content is protected !!